Publications by authors named "A Santagostino"
The TOPASE study was set up to evaluate the outcomes of chronic myeloid leukaemia [CML] patients treated with ponatinib (PON) in a real-world setting in France. One hundred and twenty CML patients, 105 in chronic phase (CP), 8 in accelerated phase (AP) and 7 in blastic phase (BP) were included. Fifty-one (49%) of the CP-CML patients were in third line of treatment.
View Article and Find Full Text PDFArticle Synopsis
- Venetoclax-azacitidine is the standard treatment for unfit acute myeloid leukemia patients, but there is limited data on how long patients should continue therapy if they cannot tolerate it.
- In a study analyzing patients who stopped treatment due to poor tolerance, those who discontinued showed comparable outcomes to those who continued with azacitidine alone, with median overall survival of 44 months for newly diagnosed patients.
- The findings suggest that patients who stop treatment while in remission can have favorable outcomes, indicating a need for further controlled trials to explore optimal treatment durations.
Article Synopsis
- CD38-targeting immunotherapy combined with lenalidomide and dexamethasone is the current best standard of care for newly diagnosed multiple myeloma patients who can't undergo transplants.
- A phase 3 study involving 270 patients tested the effectiveness of adding weekly bortezomib to this regimen, comparing the outcomes of the combination (Isa-VRd) against the standard (IsaRd).
- Results showed a significantly higher rate of minimal residual disease negativity at 18 months and better response rates in the Isa-VRd group, suggesting it could become the new standard of care for these patients.
Background: Degenerative spondylolisthesis is a disease characterized by the displacement of a vertebra above the underlying vertebra. Lumbar arthrodesis is currently the most frequently performed surgical option for treatment due to the use of various approaches and techniques. The disease is characterized by low back pain, a clinical and public health problem, which in addition to having a socio-economic burden, severely affects functional status, quality of life (QoL), activity impairment, and health services.
View Article and Find Full Text PDFBackground: Recently, the combination of venetoclax plus a hypomethylating agent (HMA; azacitidine ordecitabine) or low-dose cytarabine (LDAC) showed promise in Phase III trials in previously untreated AML. In France at the time of this study, venetoclax was not yet approved for AML and there were therefore no formal usage recommendations. Here we report the first study in a French cohort that assessed venetoclax in combination with existing treatments for AML under real-life conditions.
View Article and Find Full Text PDF